HUNTSMAN CANCER INSTITUTE: OVERALL ABSTRACT Huntsman Cancer Institute (HCI) at the University of Utah (U of U) is the only National Cancer Institute (NCI)-designated Cancer Center in its catchment area, the State of Utah. It serves as the advanced cancer care center for the State, with a dedicated cancer specialty hospital, training programs for cancer researchers and health care professionals, and a major commitment to cancer research?with depth and breadth that spans basic laboratory research; clinical research, including early phase clinical trials; and prevention, control, and population-based research. HCI effectively promotes research and public policy measures to address pressing needs of its catchment area, particularly special cancer burdens of rural/frontier populations. HCI is also the only NCI-designated Cancer Center in the five-state Mountain West (Utah, Idaho, Montana, Nevada, and Wyoming). HCI fills a critical role in the national Cancer Centers Program, by serving as a resource for this large geographical area. Our Cancer Center has 186 members drawn from 34 academic departments in nine colleges at the U of U. The members are supported by $48.7M (DC) in extramural cancer research funding. HCI research is organized into four Research Programs that provide an environment of cancer focus and collaborative exchange: ? Nuclear Control of Cell Growth and Differentiation ? Experimental Therapeutics ? Cell Response and Regulation ? Cancer Control and Population Sciences HCI advances transdisciplinary and translational research through thoughtful strategic planning, effective organizational structures, collaborative recruitment, and targeted investment. HCI members published 2,174 cancer-focused, peer-reviewed publications from 2014-2018, of which 80% are collaborative, either within the Cancer Center or with external research partners. Support is requested for six HCI Shared Resources that provide access to specialized instrumentation, assays, services, research materials, and expert consultation and collaboration. These Shared Resources include the following: ? Utah Population Database ? Cancer Biostatistics ? Genetic Counseling ? Biorepository and Molecular Pathology ? Research Informatics ? High-Throughput Genomics and Bioinformatic Analysis In summary, HCI requests funds to support Years 31-35 of our Cancer Center Support Grant (CCSG), under the leadership of Cornelia Ulrich, MS, PhD, HCI?s Cancer Center Director. CCSG funding will support expenses associated with Community Outreach and Engagement, Cancer Research Career Enhancement and Related Activities, Cancer Center Shared Resources, Clinical Protocol and Data Management, Protocol Review and Monitoring, Program Leadership, Senior Leadership, Administration, and Developmental Funds.

Public Health Relevance

HUNTSMAN CANCER INSTITUTE PROJECT NARRATIVE Huntsman Cancer Institute (HCI) at the University of Utah is the only National Cancer Institute-designated Cancer Center in Utah and the vast area of the five-state Mountain West; HCI effectively promotes research and public policy to address pressing needs of this region, particularly the special cancer burdens of rural/frontier populations. We care deeply about the next generation of cancer researchers and have implemented a portfolio of programs, including special initiatives for rural and disadvantaged youth. Through the Cancer Center Support Grant, we will make high-impact scientific discoveries across basic laboratory; clinical; and prevention, cancer control, and population-based research, and disseminate these findings to improve outcomes for individuals impacted by cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA042014-31
Application #
9935877
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-05-09
Project End
2025-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
31
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Utah
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Zeng, Tao; Fleming, Aaron M; Ding, Yun et al. (2018) Nanopore Analysis of the 5-Guanidinohydantoin to Iminoallantoin Isomerization in Duplex DNA. J Org Chem 83:3973-3978
Himbert, Caroline; Ose, Jennifer; Nattenmüller, Johanna et al. (2018) Body fatness, adipose tissue compartments and biomarkers of inflammation and angiogenesis in colorectal cancer: the ColoCare Study. Cancer Epidemiol Biomarkers Prev :
Madison, Bethany J; Clark, Kathleen A; Bhachech, Niraja et al. (2018) Electrostatic repulsion causes anticooperative DNA binding between tumor suppressor ETS transcription factors and JUN-FOS at composite DNA sites. J Biol Chem 293:18624-18635
Arbeeva, Liubov S; Hanson, Heidi A; Arbeev, Konstantin G et al. (2018) How Well Does the Family Longevity Selection Score Work: A Validation Test Using the Utah Population Database. Front Public Health 6:277
Patel, Ami B; Lange, Thoralf; Pomicter, Anthony D et al. (2018) Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib. Oncotarget 9:17889-17894
De, Shrutokirti; Van Deren, Donn; Peden, Eric et al. (2018) Two distinct ontogenies confer heterogeneity to mouse brain microglia. Development 145:
Giraddi, Rajshekhar R; Chung, Chi-Yeh; Heinz, Richard E et al. (2018) Single-Cell Transcriptomes Distinguish Stem Cell State Changes and Lineage Specification Programs in Early Mammary Gland Development. Cell Rep 24:1653-1666.e7
Doherty, Jennifer A; Grieshober, Laurie; Houck, John R et al. (2018) Telomere Length and Lung Cancer Mortality among Heavy Smokers. Cancer Epidemiol Biomarkers Prev 27:829-837
Wagner, Alex H; Devarakonda, Siddhartha; Skidmore, Zachary L et al. (2018) Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Nat Commun 9:3787
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551

Showing the most recent 10 out of 1193 publications